Oscotec Inc, a clinical stage drug discovery and development company, and ADEL Inc., a Korea-based biotech company, announced on Thursday that they have received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application of ADEL-Y01 intended for treating Alzheimer's disease (AD).
Both companies are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) aimed at tau protein accumulation in the AD brain. The product is a recombinant IgG1 class type monoclonal humanised antibody that recognises and binds to tau protein acetylated at lysine-280 (acK280), stopping aggregation and propagation of tau seeds and improving microglial tau clearance.
A phase 1a/1b study is being conduction to assess the safety, tolerability, pharmacokinetics, and clinical activity of the product in healthy volunteers and in participants with Mild Cognitive Impairment due to Alzheimer's disease or mild Alzheimer's disease.
Dr Taeyoung Yoon, CEO/CSO of Oscotec, said, 'We are convinced that ADEL-Y01 has the strong potential to be a much needed treatment option for patients with Alzheimer's disease based on its novel mechanism of action and the strength of preclinical data. Initiating the first-in-human study of ADEL-Y01 is a significant milestone to the Oscotec-Adel partnership, which also serves as a vehicle for Oscotec in expanding its R&D horizon beyond small molecule.'
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA grants interchangeability status to SELARSDI from Alvotech and Teva
Pykus Therapeutics' PYK-2101 achieves positive interim clinical trial results
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
SKNV launches Kefunova Cream for actinic keratosis and superficial basal cell carcinoma
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF